Responses
Regular and young investigator award abstracts
Clinical trials in progress
322 Efficacy and safety of GX-I7 plus pembrolizumab for heavily pretreated patients with metastatic triple negative breast cancer: The Phase 1b/2 KEYNOTE-899 Study
Compose a Response to This Article
Other responses
No responses have been published for this article.